# Democratizing Cardiovascular AI: Multi-Collection RAG Architecture for Integrated Cardiac Decision Support

**Author:** Adam Jones
**Date:** March 2026
**Version:** 1.0.0
**License:** Apache 2.0

Part of the HCLS AI Factory -- an end-to-end precision medicine platform built on three GPU-accelerated engines: the Genomic Foundation Engine (Parabricks/DeepVariant/BWA-MEM2), the Precision Intelligence Network (11 domain-specific RAG agents including this one), and the Therapeutic Discovery Engine (BioNeMo/MolMIM/DiffDock/RDKit).

---

## Abstract

Cardiovascular disease (CVD) remains the leading cause of death globally, claiming approximately 17.9 million lives annually -- representing 32% of all deaths worldwide. Despite the availability of robust clinical guidelines from ACC/AHA/ESC and exponential growth in cardiovascular AI research (over 4,500 publications in 2025 alone), critical barriers persist in clinical translation: fragmented evidence across modalities, siloed data systems, lack of integrated genomic-imaging correlation, and prohibitive infrastructure costs that limit advanced cardiac AI to elite academic centers.

This paper presents the Cardiology Intelligence Agent, a multi-collection retrieval-augmented generation (RAG) system purpose-built for cardiovascular medicine. The agent unifies 12 specialized Milvus vector collections spanning cardiac imaging, electrophysiology, hemodynamics, heart failure management, valvular heart disease, preventive cardiology, interventional cardiology, and cardio-oncology -- alongside a shared genomic_evidence collection containing 3.5 million variant vectors. The system implements 6 validated cardiovascular risk calculators (ASCVD Pooled Cohort Equations, HEART Score, CHA2DS2-VASc, HAS-BLED, MAGGIC, EuroSCORE II), optimizes guideline-directed medical therapy (GDMT) for heart failure with 7 therapy classes (including finerenone, omecamtiv, and sotagliflozin), and provides 11 clinical workflows covering the highest-impact cardiovascular use cases.

Deployed on a single NVIDIA DGX Spark ($4,699) using BGE-small-en-v1.5 embeddings (384-dimensional, IVF_FLAT, COSINE) and Claude Sonnet 4.6 for evidence synthesis, the platform democratizes access to integrated cardiovascular intelligence that currently requires multi-million-dollar institutional investments.

---

## Table of Contents

1. [Introduction](#1-introduction)
2. [Clinical Rationale](#2-clinical-rationale)
3. [Architecture](#3-architecture)
4. [Multi-Collection RAG Approach](#4-multi-collection-rag-approach)
5. [Risk Calculators](#5-risk-calculators)
6. [GDMT Framework](#6-gdmt-framework)
7. [Cross-Modal Genomic Integration](#7-cross-modal-genomic-integration)
8. [Knowledge Graph Design](#8-knowledge-graph-design)
9. [Clinical Validation Approach](#9-clinical-validation-approach)
10. [Comparison with Existing Solutions](#10-comparison-with-existing-solutions)
11. [Performance on DGX Spark](#11-performance-on-dgx-spark)
12. [Pediatric Oncology Applications](#12-pediatric-oncology-applications)
13. [Limitations and Future Work](#13-limitations-and-future-work)
14. [Conclusion](#14-conclusion)
15. [References](#15-references)

---

## 1. Introduction

### 1.1 The Cardiovascular Disease Burden

Cardiovascular disease represents the single largest cause of mortality and morbidity worldwide. According to the World Health Organization and the American Heart Association (AHA) 2025 Heart Disease and Stroke Statistics Update:

- **17.9 million deaths annually** -- 32% of all global deaths
- **523 million people** currently living with cardiovascular disease
- **$407 billion** in direct and indirect costs in the United States alone (2024)
- **Heart failure** affects 64.3 million people globally, with 5-year mortality rates exceeding 50%
- **Atrial fibrillation** prevalence has reached 59 million cases worldwide, with a projected 72 million by 2030

Despite these numbers, cardiovascular AI adoption in clinical practice remains in early stages. A 2025 ACC survey found that while 89% of cardiologists believe AI will transform their practice, only 23% currently use AI-assisted tools in routine clinical decision-making.

### 1.2 The Opportunity for Integrated Intelligence

The cardiovascular domain is uniquely suited for an integrated AI intelligence agent because:

1. **Multi-modal data convergence**: Cardiology routinely integrates imaging (echo, CT, MRI, nuclear), electrophysiology (ECG, Holter), hemodynamics (catheterization), biomarkers (troponin, BNP, lipids), genomics (familial cardiomyopathy, channelopathies), and clinical risk scores.

2. **Established clinical guidelines**: ACC/AHA guidelines provide structured frameworks for risk stratification, treatment decisions, and follow-up protocols that can be encoded into decision support logic.

3. **Quantitative measurement-rich**: Cardiology generates highly quantitative data (ejection fraction percentages, valve gradients in mmHg, calcium scores in Agatston units, QTc intervals in milliseconds) well-suited for structured RAG retrieval.

4. **Strong cross-modal triggers**: Cardiac imaging findings (e.g., unexplained left ventricular hypertrophy) frequently trigger genomic workup (hypertrophic cardiomyopathy gene panel), which may lead to drug therapy optimization.

### 1.3 Our Contribution

This paper presents the sixth domain-specific intelligence agent in the HCLS AI Factory platform, following the Precision Biomarker, Precision Oncology, CAR-T, Imaging, and Autoimmune agents. Our contributions include:

- A **12-collection Milvus vector schema** spanning the full cardiovascular data spectrum
- **Eleven clinical workflows** covering coronary artery disease, heart failure, valvular disease, arrhythmia, cardiac MRI, stress testing, preventive risk stratification, cardio-oncology, acute decompensated HF, post-MI, and myocarditis/pericarditis
- A **cardiovascular knowledge graph** with 45 conditions, 29 biomarkers, 32 drug classes, 56 genes, 27 imaging protocols, and 51 guideline recommendations across 20 guideline documents
- **Six validated risk calculators** with published coefficients and lookup tables
- A **GDMT optimizer** supporting 7 therapy classes for evidence-based heart failure medication management
- **Cross-modal triggers** with 18 genomic trigger patterns linking imaging findings to genomic workup panels
- **Deployment on a single NVIDIA DGX Spark** ($4,699)

---

## 2. Clinical Rationale

### 2.1 Why Cardiology Needs Integrated AI

Cardiovascular clinical practice generates data across at least fifteen distinct categories, each with its own structure, vocabulary, source systems, and update cadences. A cardiologist evaluating a patient with dyspnea must synthesize:

- **Echocardiographic data**: LVEF, diastolic parameters (E/e', LA volume), valve function, GLS
- **Biomarkers**: NT-proBNP, troponin, lipid panel, creatinine, potassium
- **ECG findings**: Rhythm, intervals (PR, QRS, QTc), axis, ST/T changes
- **Clinical risk scores**: CHA2DS2-VASc for AF, ASCVD for prevention, MAGGIC for HF prognosis
- **Medication review**: GDMT status for each of the four pillars
- **Imaging history**: Prior cardiac MRI tissue characterization, stress test results
- **Genomic data**: Family history suggesting inherited cardiomyopathy
- **Guidelines**: Current ACC/AHA/ESC recommendations applicable to the clinical scenario

No existing tool integrates all of these data streams into a unified clinical decision support framework.

### 2.2 The Data Fragmentation Problem

| Data Source | Update Frequency | Format | Typical Access |
|-------------|-----------------|--------|---------------|
| PubMed literature | Daily | Unstructured text | Keyword search |
| ACC/AHA guidelines | Every 2-5 years | PDF | Manual review |
| Echo reports | Per-study | Semi-structured | EHR |
| ECG data | Per-recording | Signal + text | EHR/PACS |
| Biomarker results | Per-order | Structured numeric | EHR |
| ClinicalTrials.gov | Continuous | Semi-structured | Web search |
| FDA device clearances | Continuous | Semi-structured | Web search |
| Genomic testing | Per-test | VCF/structured | Separate platform |

The Cardiology Intelligence Agent bridges these silos by embedding all data types into a unified 384-dimensional vector space, enabling semantic search across modalities.

### 2.3 Target Users and Use Cases

| User | Primary Use Case |
|------|-----------------|
| **General cardiologists** | Evidence lookup, risk calculation, GDMT optimization |
| **Interventional cardiologists** | Pre-procedural risk assessment, CAD-RADS interpretation |
| **Electrophysiologists** | Arrhythmia classification, anticoagulation decision support |
| **HF specialists** | GDMT titration guidance, device eligibility assessment |
| **Imaging cardiologists** | Cross-modal trigger identification, tissue characterization reference |
| **Cardio-oncologists** | Cardiotoxicity surveillance protocols, CTRCD detection |
| **Preventive cardiologists** | ASCVD risk stratification, statin eligibility, CAC interpretation |
| **Trainees** | Evidence-based learning, guideline reference |

---

## 3. Architecture

### 3.1 System Architecture

The Cardiology Intelligence Agent follows a layered architecture:

```
+------------------------------------------------------------------+
|                     Presentation Layer                             |
|   Streamlit UI (:8536)  |  FastAPI REST API (:8126)               |
+------------------------------------------------------------------+
|                     Application Layer                              |
|   Agent Orchestrator  |  Workflow Engine  |  Export System         |
+------------------------------------------------------------------+
|                     Clinical Engine Layer                           |
|   Risk Calculators  |  GDMT Optimizer  |  Cross-Modal Engine     |
+------------------------------------------------------------------+
|                     Intelligence Layer                              |
|   RAG Engine  |  Query Expansion  |  Citation Scoring  |  LLM    |
+------------------------------------------------------------------+
|                     Data Layer                                      |
|   Milvus (12+1 collections)  |  Knowledge Graph  |  Cache        |
+------------------------------------------------------------------+
|                     Infrastructure Layer                            |
|   Docker Compose  |  Prometheus  |  APScheduler  |  DGX Spark    |
+------------------------------------------------------------------+
```

### 3.2 Technology Decisions

| Decision | Choice | Rationale |
|----------|--------|-----------|
| Vector DB | Milvus 2.4 | Proven at scale in HCLS AI Factory; IVF_FLAT supports 3.5M+ vectors |
| Embeddings | BGE-small-en-v1.5 | 384-dim balances quality and memory; consistent with other agents |
| LLM | Claude Sonnet 4.6 | Strong clinical reasoning; citation adherence; safety guardrails |
| Index type | IVF_FLAT | High recall for clinical queries; acceptable latency on DGX Spark |
| Similarity | COSINE | Standard for normalized text embeddings |
| API framework | FastAPI | Async support, auto-docs, Pydantic integration |
| UI framework | Streamlit | Rapid prototyping, interactive widgets, clinical dashboard support |

### 3.3 Codebase Statistics

The agent comprises 28,189 lines of Python across 37 source files:

| Component | Files | LOC | Percentage |
|-----------|-------|-----|-----------|
| Core engine (src/) | 13 | 20,234 | 71.8% |
| Ingest parsers (src/ingest/) | 8 | 3,742 | 13.3% |
| API layer (api/) | 4 | 1,906 | 6.8% |
| UI (app/) | 1 | 1,182 | 4.2% |
| Scripts | 3 | 918 | 3.3% |
| Config | 1 | 181 | 0.6% |

---

## 4. Multi-Collection RAG Approach

### 4.1 Collection Design Rationale

The cardiovascular domain requires distinct vector collections because:

1. **Semantic boundaries**: The word "gradient" means something entirely different in aortic stenosis (pressure gradient in mmHg) vs. preventive cardiology (risk gradient) vs. cardiac MRI (field gradient). Collection-specific embeddings preserve semantic precision.

2. **Relevance weighting**: A query about GDMT optimization should weight heart failure collection results higher than imaging collection results, while a query about LGE patterns should do the opposite.

3. **Update cadences**: PubMed literature updates daily; guidelines update every 2-5 years. Separate collections allow independent refresh cycles.

4. **Source attribution**: Clinicians need to know whether a citation comes from a randomized trial, a guideline, or an imaging protocol document.

### 4.2 The 12+1 Collection Schema

| Collection | Source | Typical Content |
|-----------|--------|-----------------|
| cardio_literature | PubMed | Abstracts, reviews, meta-analyses |
| cardio_trials | ClinicalTrials.gov | Trial designs, results, endpoints |
| cardio_imaging | Imaging society docs | Protocols, measurements, reference values |
| cardio_electrophysiology | EP literature/data | ECG interpretation, arrhythmia algorithms |
| cardio_heart_failure | HF guidelines/trials | GDMT, staging, biomarker thresholds |
| cardio_valvular | VHD guidelines | Severity criteria, intervention thresholds |
| cardio_prevention | Prevention guidelines | Risk calculation, statin criteria, lifestyle |
| cardio_interventional | Interventional data | PCI, structural, procedural outcomes |
| cardio_oncology | Cardio-onc guidelines | Cardiotoxicity, surveillance, CTRCD |
| cardio_devices | FDA database | AI/ML clearances, implantable devices |
| cardio_guidelines | ACC/AHA/ESC | Structured recommendations with class/LOE |
| cardio_hemodynamics | Cath data | Pressure tracings, derived calculations |
| genomic_evidence | HCLS AI Factory | 3.5M variant vectors (shared, read-only) |

### 4.3 Weighted Multi-Collection Search

Each query is routed to all relevant collections. Results are scored as:

```
final_score = similarity_score * collection_weight * workflow_boost
```

Collection weights sum to 1.0 and can be dynamically adjusted based on the detected workflow type. For example, a heart failure query boosts `cardio_heart_failure` (0.10 -> 0.25) and `cardio_guidelines` (0.10 -> 0.20) while reducing less relevant collections.

### 4.4 Query Expansion Pipeline

The query expansion module (2,025 lines) implements a multi-stage expansion:

1. **Entity extraction**: Identifies conditions, drugs, imaging modalities, and biomarkers from the query using the knowledge graph (167 entity aliases across 18 synonym maps)
2. **Synonym expansion**: Expands abbreviations (e.g., "HCM" -> "hypertrophic cardiomyopathy, HOCM, IHSS")
3. **Sub-question decomposition**: Breaks complex clinical questions into searchable sub-questions
4. **Strategy selection**: Chooses between broad, targeted, comparative, and clinical search strategies
5. **Collection routing**: Adjusts collection weights based on identified entities and workflow type

---

## 5. Risk Calculators

### 5.1 Design Philosophy

The Cardiology Intelligence Agent implements 6 validated cardiovascular risk calculators with the following principles:

1. **Published coefficients**: All calculators use published regression coefficients, not approximations
2. **Input validation**: Each calculator validates required inputs and provides descriptive error messages
3. **Risk stratification**: Output includes numeric score, risk category, clinical interpretation, and actionable recommendations
4. **Guideline references**: Each result cites the source publication and applicable guideline

### 5.2 ASCVD Pooled Cohort Equations

The 10-year ASCVD risk calculator implements the Goff 2013 Pooled Cohort Equations with separate coefficient sets for four sex/race cohorts:

| Cohort | Baseline Survival (S0) | Mean Coefficient |
|--------|----------------------|-----------------|
| White female | 0.9665 | -29.18 |
| African American female | 0.9533 | 86.61 |
| White male | 0.9144 | 61.18 |
| African American male | 0.8954 | 19.54 |

The individual sum incorporates: ln(age), ln(total cholesterol), ln(HDL), ln(SBP) with treatment interaction, smoking status, and diabetes. The 10-year risk is computed as:

```
risk = 1 - S0^exp(individual_sum - mean_coefficient)
```

Risk categories: Low (<5%), Borderline (5-7.5%), Intermediate (7.5-20%), High (>=20%)

### 5.3 CHA2DS2-VASc and HAS-BLED

These paired calculators support anticoagulation decision-making in atrial fibrillation:

**CHA2DS2-VASc** (stroke risk): Uses published annual stroke rate lookup table (Lip 2010) mapping integer scores 0-9 to stroke rates from 0.0% to 15.2%.

**HAS-BLED** (bleeding risk): Scores 0-9 with risk categories: Low (0-1), Moderate (2), High (>=3). A high HAS-BLED score does not contraindicate anticoagulation but mandates closer monitoring.

### 5.4 MAGGIC Heart Failure Risk Score

The MAGGIC score uses a point-based system incorporating 13 variables to predict 1-year and 3-year mortality. The implementation includes full 51-tier lookup tables (score 0-50) for both timepoints, derived from Pocock et al. (2013).

### 5.5 EuroSCORE II

The EuroSCORE II logistic regression model uses 28 beta coefficients across patient-related, cardiac-related, and operation-related factors. The predicted mortality is:

```
logit = beta0 + sum(beta_i * x_i)
predicted_mortality = exp(logit) / (1 + exp(logit))
```

Where beta0 = -5.324537 (intercept).

---

## 6. GDMT Framework

### 6.1 The GDMT Optimization Challenge

Guideline-directed medical therapy for heart failure with reduced ejection fraction involves simultaneous management of four drug pillars, each with specific initiation criteria, uptitration schedules, target doses, contraindications, and monitoring requirements. Studies show that fewer than 25% of eligible HFrEF patients are on target doses of all four GDMT pillars.

### 6.2 Four-Pillar Implementation

The GDMT optimizer (2,457 lines) manages:

| Pillar | Initiation Check | Titration Logic | Target Dose |
|--------|-----------------|-----------------|-------------|
| Beta-blocker | HR >60, SBP >90, no acute decompensation | Double dose q2 weeks if tolerated | Carvedilol 25mg BID |
| ARNI | SBP >100, K+ <5.0, eGFR >20, 36h ACEi washout | Double dose q2-4 weeks | 97/103mg BID |
| MRA | K+ <5.0, eGFR >30 | Check K+ at 1 week, 4 weeks | Spironolactone 25-50mg |
| SGLT2i | eGFR >20 (initiation) | No titration needed | Dapagliflozin 10mg |

### 6.3 EF-Stratified Recommendations

| EF Category | GDMT Approach |
|-------------|---------------|
| HFrEF (LVEF <=40%) | Full 4-pillar GDMT; simultaneous initiation if possible |
| HFmrEF (LVEF 41-49%) | SGLT2i (Class I); consider ARNI, beta-blocker, MRA |
| HFpEF (LVEF >=50%) | SGLT2i (Class I); diuretics; treat comorbidities; GLP-1 RA if obese |
| HFimpEF | Continue all GDMT indefinitely; do not de-escalate based on improved EF |

### 6.4 Additional Therapies

The optimizer also evaluates eligibility for:
- **H-ISDN**: For African American patients with NYHA III-IV symptoms
- **Ivabradine**: For sinus rhythm, HR >=70, LVEF <=35% on maximally tolerated beta-blocker
- **IV iron**: For ferritin <100 or (100-299 with TSAT <20%)
- **Device therapy**: ICD (LVEF <=35% on GDMT >=90 days) and CRT (LBBB + QRS >=150ms + LVEF <=35%)

---

## 7. Cross-Modal Genomic Integration

### 7.1 The Cross-Modal Paradigm

One of the most clinically valuable features of the Cardiology Intelligence Agent is the automated cross-modal trigger system that links cardiac imaging findings to genomic workup recommendations. This bridges the traditional gap between the imaging lab and the genetics clinic.

### 7.2 Trigger Architecture

The cross-modal engine (1,734 lines) implements a pattern-matching system:

1. **Trigger definition**: Eighteen imaging-to-genomic trigger patterns are defined in the knowledge graph, each mapping an imaging finding to a recommended gene panel and list of suspected conditions.

2. **Pattern matching**: After each workflow execution, the engine scans imaging findings against the trigger definitions using both exact match and semantic similarity.

3. **Genomic evidence retrieval**: For matched triggers, the shared `genomic_evidence` collection (3.5M variants) is queried for relevant variant data.

4. **Clinical contextualization**: Each trigger includes a clinical rationale explaining why the imaging finding warrants genetic testing, with guideline references.

### 7.3 Clinical Examples

**Example 1: Unexplained LVH**
- Echocardiogram shows interventricular septum thickness of 18mm
- No history of hypertension or aortic stenosis
- Cross-modal trigger fires: recommend HCM gene panel (MYH7, MYBPC3, TNNT2, TNNI3, TPM1) + Fabry disease testing (GLA) + Danon disease testing (LAMP2)
- Genomic_evidence collection is queried for known pathogenic variants in these genes

**Example 2: Aortic Root Dilation in Young Patient**
- Cardiac CT shows aortic root diameter 4.5cm in a 28-year-old
- Cross-modal trigger fires: recommend aortopathy gene panel (FBN1, TGFBR1, TGFBR2, SMAD3, ACTA2, MYH11, COL3A1)
- Identifies Marfan syndrome, Loeys-Dietz syndrome, and familial TAAD as diagnostic considerations
- May influence surgical threshold (5.0cm for Marfan vs 5.5cm for degenerative)

**Example 3: Premature Coronary Disease**
- Coronary CTA shows significant CAD in a 42-year-old male with LDL 245 mg/dL
- Cross-modal trigger fires: recommend FH gene panel (LDLR, PCSK9, APOB)
- Cascade family screening recommendation generated for first-degree relatives

---

## 8. Knowledge Graph Design

### 8.1 Graph Structure

The cardiovascular knowledge graph (1,431 lines) serves as the domain ontology for the system, providing structured data across 7 categories and 320+ total entries:

| Category | Entries | Key Fields |
|----------|---------|-----------|
| Conditions | 45 | Aliases, ICD-10, prevalence, diagnostic criteria, genes, guidelines |
| Biomarkers | 29 | LOINC codes, reference ranges, kinetics, guideline thresholds |
| Drug Classes | 32 | Mechanisms, indications, contraindications, target doses, key trials |
| Genes | 56 | Chromosome, function, conditions, inheritance, key variants |
| Imaging Modalities | 27 | Protocols (12 echo, 7 CMR, 5 nuclear, 3 CT), measurements, reference values |
| Guideline Recommendations | 63 | Class, evidence level, society, year, condition (across 20 guideline documents) |
| Entity Aliases | 167 | Abbreviation-to-full-name mappings (18 synonym maps) |

### 8.2 Cross-Referencing

The knowledge graph enables rich cross-referencing:

- **Condition -> Genes**: HCM maps to MYH7, MYBPC3, TNNT2, TNNI3, TPM1, ACTC1, MYL2, MYL3
- **Condition -> Drug Classes**: HFrEF maps to beta_blockers, arni, mra, sglt2_inhibitors, loop_diuretics, hydralazine_isdn, ivabradine, digoxin
- **Condition -> Imaging**: HCM maps to echocardiography, cardiac_mri, cardiac_ct
- **Imaging Finding -> Gene Panel**: Unexplained LVH maps to HCM/Fabry/Danon gene panel
- **Drug -> Key Trials**: Sacubitril/valsartan maps to PARADIGM-HF, PARAGON-HF
- **Drug -> Monitoring**: MRA maps to potassium (1 week, 4 weeks, then quarterly), creatinine, gynecomastia

### 8.3 Entity Resolution

The 167 entity alias entries enable robust entity resolution during query expansion. For example, the query "What is the recommended anticoagulation for a patient with AF and CHA2DS2-VASc of 3?" triggers the following resolutions:

- "AF" -> "atrial fibrillation"
- "CHA2DS2-VASc" -> recognized as risk score type
- "anticoagulation" -> maps to drug classes: doacs, warfarin

---

## 9. Clinical Validation Approach

### 9.1 Validation Strategy

Clinical validation of the Cardiology Intelligence Agent follows a three-phase approach:

**Phase 1: Calculator Validation**
- Each risk calculator is validated against published example calculations from source papers
- ASCVD PCE: validated against ACC ASCVD Risk Estimator Plus
- CHA2DS2-VASc/HAS-BLED: validated against MDCalc reference implementations
- MAGGIC: validated against published score-to-mortality lookup tables
- EuroSCORE II: validated against euroscore.org calculator

**Phase 2: GDMT Optimization Validation**
- GDMT recommendations validated against ACC/AHA 2022 HF guideline decision algorithms
- Contraindication checking validated against published criteria
- Titration sequences validated against published uptitration protocols
- Edge cases (renal impairment, hyperkalemia, hypotension) validated against expert consensus

**Phase 3: RAG Quality Validation**
- Clinical vignette testing across all 11 workflows
- Citation accuracy assessment (does the cited source support the claim?)
- Hallucination detection (does the response contain unsupported statements?)
- Guideline concordance (does the recommendation align with current ACC/AHA/ESC guidelines?)

### 9.2 Safety Guardrails

The system implements multiple safety measures:

1. **Disclaimer**: All outputs include a clinical disclaimer noting that the system is a decision support tool and does not replace clinical judgment
2. **Confidence scoring**: Each response includes a confidence score (0.0-1.0) based on citation quality and coverage
3. **Citation provenance**: Every clinical claim traces to a specific source with similarity score
4. **Risk score validation**: Input parameters are validated with clinical range checks (e.g., age 18-120, SBP 60-300)
5. **Contraindication flagging**: GDMT optimizer flags all active contraindications before making recommendations

---

## 10. Comparison with Existing Solutions

| Feature | Cardio Agent | PubMed | UpToDate | Commercial CVIS | General AI |
|---------|-------------|--------|----------|----------------|-----------|
| Multi-collection RAG | 13 collections | N/A | N/A | N/A | N/A |
| Risk calculators | 6 validated | None | Links out | Limited | Unreliable |
| GDMT optimization | 4-pillar with titration | None | Reference only | None | Not validated |
| Cross-modal triggers | 18 imaging-genomic | None | None | None | None |
| Guideline-grounded | 63 structured recs | Manual search | Curated | Partial | Hallucination risk |
| Genomic integration | 3.5M variants | None | None | None | None |
| Cost | $4,699 (DGX Spark) | Free | $500/yr/user | $500K-$2M | $20/mo |
| On-premises | Yes | No | No | Yes | No |
| Citation provenance | Per-claim | Per-paper | Per-topic | N/A | None |
| Knowledge graph | 450+ structured entries | None | Expert-curated | Vendor-specific | None |

---

## 11. Performance on DGX Spark

### 11.1 Hardware Specifications

The NVIDIA DGX Spark provides:
- NVIDIA Grace CPU (72 ARM cores)
- NVIDIA Blackwell GPU (128GB unified memory)
- 128GB LPDDR5X unified memory
- NVMe SSD storage

### 11.2 Performance Characteristics

| Operation | Expected Latency | Notes |
|-----------|-----------------|-------|
| Embedding generation | ~50ms per query | BGE-small-en-v1.5 on GPU |
| Multi-collection search | ~200ms | 13 collections, top_k=5 each |
| Risk calculation | <5ms | Pure computation, no I/O |
| GDMT optimization | <10ms | Rule-based logic |
| Cross-modal trigger | ~100ms | Pattern match + genomic lookup |
| LLM synthesis | 2-5s | Claude Sonnet 4.6 API call |
| **Total end-to-end** | **<5s** | Query to response |

### 11.3 Memory Footprint

| Component | Memory |
|-----------|--------|
| Milvus (12 collections) | ~2-4 GB (depends on vector count) |
| Milvus (genomic_evidence, 3.5M) | ~8-10 GB |
| BGE-small-en-v1.5 model | ~130 MB |
| Application stack | ~500 MB |
| etcd + MinIO | ~200 MB |
| **Total** | **~12-15 GB** |

---

## 12. Pediatric Oncology Applications

### 12.1 Anthracycline Cardiotoxicity in Childhood Cancer Survivors

Cardiotoxicity is the leading non-relapse cause of morbidity and mortality in childhood cancer survivors. The Cardiology Intelligence Agent addresses this through a dedicated `pediatric_cardiotoxicity_assessment()` module within the cardio-oncology workflow:

- **Incidence**: Anthracycline-induced cardiotoxicity occurs in 5-25% of pediatric patients as a late-onset effect, often manifesting years to decades after treatment completion
- **Cumulative dose monitoring**: The system tracks cumulative anthracycline dose against established thresholds -- 250 mg/m2 (trigger for increased surveillance and dexrazoxane consideration) and 450 mg/m2 (high-risk threshold for clinical cardiotoxicity)
- **Dexrazoxane cardioprotection**: The agent recommends dexrazoxane for pediatric patients approaching cumulative doxorubicin doses of 250 mg/m2, per Children's Oncology Group (COG) supportive care guidelines
- **Pediatric echo monitoring protocol**: Generates surveillance schedules aligned with COG Long-Term Follow-Up (LTFU) guidelines -- baseline echocardiography, mid-treatment GLS assessment, end-of-treatment evaluation, and structured long-term follow-up at 1, 2, 5, and 10 years post-therapy
- **Cross-modal integration**: Imaging findings (LVEF decline, GLS reduction) trigger genomic workup for underlying cardiomyopathy susceptibility (TTN, LMNA, MYH7) that may compound treatment-related cardiotoxicity

### 12.2 Cross-Agent Coordination for Pediatric Cardio-Oncology

The cardiology agent coordinates with 4 sibling agents for pediatric cardiotoxicity cases:

1. **Oncology Agent**: Receives cumulative chemotherapy doses, treatment protocol details, and relapse risk context
2. **Clinical Trial Agent**: Identifies active pediatric cardioprotection trials and late-effects studies
3. **Biomarker Agent**: Tracks longitudinal troponin and BNP trajectories for early cardiotoxicity detection
4. **Imaging Agent**: Correlates serial echo measurements with treatment timelines

---

## 13. Limitations and Future Work

### 12.1 Current Limitations

1. **No real-time ECG analysis**: The system interprets ECG reports but does not analyze raw ECG signals
2. **No direct DICOM processing**: Imaging data must be pre-processed into text reports
3. **LLM dependency**: Claude Sonnet 4.6 requires API connectivity; offline mode is search-only
4. **No EHR integration**: Manual data entry required; no HL7/FHIR inbound feeds
5. **Single-language**: English only for current guideline and literature collections
6. **Validation scope**: Calculator validation completed; full clinical workflow validation in progress

### 12.2 Future Directions

1. **NVIDIA NIM integration**: On-device LLM inference for fully offline operation
2. **Real-time ECG pipeline**: Direct 12-lead ECG signal analysis using on-device models
3. **FHIR interoperability**: Bidirectional EHR integration for automated data ingestion
4. **Imaging AI**: Direct DICOM analysis for echo measurements, CT calcium scoring, MRI tissue characterization
5. **Population health**: Cohort-level cardiovascular risk dashboards and quality metrics
6. **Wearable integration**: Continuous monitoring data from smartwatch ECG and activity sensors
7. **Multi-center validation**: Prospective clinical validation across diverse patient populations

---

## 14. Conclusion

The Cardiology Intelligence Agent demonstrates that comprehensive, multi-modal cardiovascular decision support can be delivered on a single desktop-class device at a fraction of the cost of traditional enterprise solutions. By combining multi-collection RAG architecture, validated clinical calculators, guideline-directed therapy optimization, and cross-modal genomic integration, the system addresses the data fragmentation that has long hindered cardiovascular AI adoption.

The open-source, Apache 2.0-licensed platform lowers the barrier to entry for any institution seeking to implement AI-assisted cardiovascular care -- from community hospitals to academic medical centers to global health systems in resource-limited settings. As cardiovascular disease continues to claim 17.9 million lives annually, democratizing access to integrated clinical intelligence is not merely an engineering achievement but a moral imperative.

---

## 15. References

1. Goff DC Jr, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. J Am Coll Cardiol. 2014;63(25 Pt B):2935-2959.
2. Lip GYH, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation. Chest 2010;137(2):263-272.
3. Pisters R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding. Chest 2010;138(5):1093-1100.
4. Six AJ, et al. Chest pain in the emergency room: value of the HEART score. Neth Heart J. 2008;16(6):191-196.
5. Pocock SJ, et al. Predicting survival in heart failure: a risk score based on 39,372 patients from 30 studies. Eur Heart J. 2013;34(19):1404-1413.
6. Nashef SA, et al. EuroSCORE II. Eur J Cardiothorac Surg. 2012;41(4):734-745.
7. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17):e263-e421.
8. Otto CM, et al. 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease. J Am Coll Cardiol. 2021;77(4):e25-e197.
9. Grundy SM, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350.
10. Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation. Circulation. 2024;149(1):e1-e156.
11. Ommen SR, et al. 2024 AHA/ACC Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2024.
12. Lyon AR, et al. 2022 ESC Guidelines on cardio-oncology. Eur Heart J. 2022;43(41):4229-4361.
13. Byrne RA, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826.
14. World Health Organization. Cardiovascular diseases fact sheet. 2025.
15. American Heart Association. 2025 Heart Disease and Stroke Statistics Update. Circulation. 2025.
